Clinical InvestigationRosiglitazone Reverses Mitomycin C Resistance in Human Gastric Cancer Cells
Section snippets
Materials
RPMI 1640 culture medium and fetal bovine serum (without Mycoplasma) was obtained from Gibco (Gibco BRL, New York, NY). VCR, methyl thiazolyl tetrazolium (MTT), trypsin and mitomycin C (MMC) were obtained from Sigma (Sigma, St. Louis, MO). The AMV first-strand cDNA synthesis kit, the ready-to-use reverse transcription polymerase chain reaction (RT-PCR) kit and primers for MDR1, including Livin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), were purchased from the Biological Engineering
ROS Reversed the Resistance of SGC7901/VCR to MMC as Determined by the MTT Assay
As shown in Figure 1, ROS reversed the resistance of SGC7901/VCR cells to MMC in a concentration-dependent manner. When the concentration of ROS increased progressively from 0 to 80 μM, the IC50 of MMC for SGC7901/ VCR cell line decreased from 9.13 to 0.87 mg/L. At 40 and 80 μM, ROS reversed the drug resistance of the SGC7901/ VCR cells, with RIs of MMC for SGC7901/VCR cells being 9.6 and 10.5, respectively, which were equal to the results with CSA (RI = 9.8, P > 0.05). These findings suggest
DISCUSSION
MDR is a significant problem in the treatment of gastric carcinomas. Many methods have been used to attempt to reverse MDR, including reversing agents, cytokines, monoclonal antibodies and various nucleic acid technologies. Reversing agents such as verapamil, cyclosporine and its derivative PSC-833, a non-immunosuppressive cyclosporine D analog and 2nd generation ABCBl/P-gp/MDRl specific reversal agent, can reverse MDR to reduce chemotherapeutic resistance to some degree. However, the severe
REFERENCES (28)
- et al.
Livin, a novel inhibitor of apoptosis protein family member
J Biol Chem
(2001) - et al.
Troglitazone induces p27Kipl-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells
Hepatology
(2003) - et al.
Epidemiology of gastric cancer
World J Gastroenterol
(2006) Incidence and mortality of gastric cancer in China
World J Gastroenterol
(2006)- et al.
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR(ABCG2)
J Cell Sci
(2000) - et al.
Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations
Anticancer Res
(2002) - et al.
Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression
Clin Cancer Res
(2008) - et al.
Establishment of multidrug resistant gastric cancer cell line and its biological characteristics (in Chinese with English abstract)
Zhongguo Zhongliu Linchuang Chin J Clin Oncol
(1994) - et al.
Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo
Acta Oncol
(1995) - et al.
Characteristics of the peroxisome proliferator activated receptor gamma (PPARamma) ligand induced apoptosis in colon cancer cells
Gut
(2002)
Herbal or natural medicines as modulators of peroxisome proliferator activated receptors and related nuclear receptors for therapy of metabolic syndrome
Pharmacol Toxicol
A study on the mechanism of growth inhibition by PPARgamma ligand rosiglitazone in the human gastric carcinoma cell line MGC803
Pract J Cancer
A study on the effects of PPAR gamma ligand rosiglitazone in the growth of MGC803 cells transplanted into subrenal-capsule of mice
Cancer Res Clin
Effect of rosiglitazone combined with all-trans retinoic acid on anti-angiogenesis of transplanted gastric cancer in nude mice
Chin J Digest
Cited by (9)
Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents
2019, Biomedicine and PharmacotherapyCitation Excerpt :P-gp and BCRP expression have been reported to decrease the anti-cancer activity of pan-aurora kinase inhibitor tozasertib but not of the aurora kinase inhibitor alisertib indicating that alisertib is not a substrate of these ABC transporters [38,39]. Two compounds, celecoxib and LY294002, have been previously shown to inhibit MRP1 efflux function [24,25] while anti-cancer drugs mifepristone and rosiglitazone although have not been reported to be a substrate or inhibitor of MRP1 directly but have been shown to reverse resistance of cells overexpressing P-gp and MRP1 [40,41]. Eleven of the 18 hit drugs have been reported previously to be a substrate or inhibitor of P-gp or BCRP but not have been reported to interact with MRP1.
Drug Repurposing in Gastric Cancer: Current Status and Future Perspectives
2023, Hereditary Gastric and Breast Cancer Syndrome: CDH1: One Genotype with Multiple PhenotypesThe research progress of the correlation between diabetes mellitus and gastric cancer
2020, Chinese Journal of Clinical NutritionMechanisms of resistance to chemotherapy in gastric cancer
2016, Anti-Cancer Agents in Medicinal ChemistryDiabetes and gastric cancer: The potential links
2014, World Journal of Gastroenterology
This work was supported by grants from the Foundation of Natural Science of Hunan Province (no. 08JJ5002), the Foundation of Science and Technology of Hunan Province (no. 2009SK3138) and the Scientific Research Foundation from Health Department of Hunan Province (no. 2007110).